NX Prenatal publishes study results on premature birth biomarkers
March 22, 2016 – LOUISVILLE, Ky., March 22, 2016. NX Prenatal, Inc. announced today that the American Journal of Obstetrics and Gynecology (“AJOG”) published a manuscript entitled, “Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth,” from a clinical study evaluating blood-based biomarkers in pregnant mothers. In the study, candidate biomarker panels comprised of exosome-associated proteins evaluated at week 10-12 of gestation were shown to effectively differentiate groups women who go on to deliver spontaneously at less than 34 weeks versus term delivering controls (≥ 37 weeks).
This optimization study enrolled 75 patients (25 spontaneous preterm cases by 50 matched full-term controls) from the prospectively collected LIFECODES cohort at Brigham & Women’s Hospital (BWH). Results indicated that:
Dr. David Cantonwine, Perinatal Epidemiologist with the Division of Maternal Fetal Medicine at BWH, commented, “Multiple other peer-reviewed publications have now identified important roles that exosomes play in mediating maternal-fetal crosstalk. To our knowledge, this is the first report that shows the potential to exploit this phenomenon for clinically useful SPTB risk stratification in the late first trimester.”
Based on these encouraging data, NX Prenatal is conducting further studies which are powered to validate a multiplex panel comprised of up to 10 biomarkers associated with clinically relevant biological processes which have consistently shown unique expression profiles across its discovery and optimization cohorts.
SOURCE NX Prenatal Inc.